Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Review Group ◽

Previously Treated ◽

Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0677-7 ◽

2018 ◽

Vol 36 (12) ◽

pp. 1427-1437 ◽

Cited By ~ 1

Author(s):

Iñigo Bermejo ◽

Shijie Ren ◽

Emma Simpson ◽

Mark Clowes ◽

David L. Scott ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Evidence Review Group ◽

Technology Appraisal ◽

Severe Rheumatoid Arthritis ◽

Review Group ◽

Previously Treated ◽

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-021-01080-z ◽

2021 ◽

Author(s):

Sabine E. Grimm ◽

Ben Wijnen ◽

Rob Riemsma ◽

Debra Fayter ◽

Nigel Armstrong ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Evidence Review Group ◽

Technology Appraisal ◽

Severe Rheumatoid Arthritis ◽

Review Group ◽

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-021-01098-3 ◽

2021 ◽

Author(s):

Sabine E. Grimm ◽

Willem Witlox ◽

Robert Wolff ◽

Annette Chalker ◽

Mickael Hiligsmann ◽

...

Keyword(s):

Mycosis Fungoides ◽

Evidence Review Group ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Technology Appraisal ◽

Review Group ◽

Previously Treated ◽

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-020-00971-x ◽

2020 ◽

Author(s):

Willem J. A. Witlox ◽

Sabine E. Grimm ◽

Rob Riemsma ◽

Nigel Armstrong ◽

Steve Ryder ◽

...

Keyword(s):

Follicular Lymphoma ◽

Marginal Zone ◽

Evidence Review Group ◽

Marginal Zone Lymphoma ◽

Technology Appraisal ◽

Review Group ◽

Previously Treated ◽

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-016-0457-1 ◽

2016 ◽

Vol 35 (4) ◽

pp. 415-424 ◽

Cited By ~ 3

Author(s):

Benjamin Kearns ◽

Abdullah Pandor ◽

Matt Stevenson ◽

Jean Hamilton ◽

Duncan Chambers ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Previously Treated ◽

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0581-6 ◽

2017 ◽

Vol 36 (2) ◽

pp. 145-159 ◽

Cited By ~ 6

Author(s):

Nasuh C. Büyükkaramikli ◽

Saskia de Groot ◽

Debra Fayter ◽

Robert Wolff ◽

Nigel Armstrong ◽

...

Keyword(s):

Multiple Myeloma ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Refractory Multiple Myeloma ◽

Previously Treated ◽

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0591-4 ◽

2017 ◽

Vol 36 (3) ◽

pp. 285-288 ◽

Cited By ~ 2

Author(s):

Bram L. T. Ramaekers ◽

Robert Wolff ◽

Anoukh van Giessen ◽

Xavier Pouwels ◽

Debra Fayter ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Previously Treated ◽

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0528-y ◽

2017 ◽

Vol 35 (12) ◽

pp. 1211-1221 ◽

Cited By ~ 9

Author(s):

Nasuh C. Büyükkaramikli ◽

Hedwig M. Blommestein ◽

Rob Riemsma ◽

Nigel Armstrong ◽

Fiona. J. Clay ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Previously Treated ◽

Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0689-3 ◽

2018 ◽

Vol 37 (1) ◽

pp. 19-27 ◽

Cited By ~ 2

Author(s):

Daniel Gallacher ◽

Xavier Armoiry ◽

Peter Auguste ◽

Rachel Court ◽

Theodoros Mantopoulos ◽

...

Keyword(s):

Urothelial Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Metastatic Urothelial Cancer ◽

Previously Treated ◽

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0521-5 ◽

2017 ◽

Vol 35 (11) ◽

pp. 1141-1151 ◽

Cited By ~ 2

Author(s):

Iñigo Bermejo ◽

Matt Stevenson ◽

Rachel Archer ◽

John W. Stevens ◽

Edward Goka ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Evidence Review Group ◽

Inadequate Response ◽

Technology Appraisal ◽

Review Group ◽

Tnf Α ◽